These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 1683625)

  • 21. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
    Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
    Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Profile of the action of neuroleptics in deficit schizophrenia].
    Vanelle JM
    Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Predictors of the course of schizophrenic diseases under neuroleptic long-term medication (author's transl)].
    Gaebel W; Pietzcker A; Poppenberg A
    Pharmacopsychiatria; 1981 Sep; 14(5):180-8. PubMed ID: 6117091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neuroleptic malignant syndrome. Case reports].
    Berardi D; Troia M; Veronesi L; Ferrari G
    Minerva Psichiatr; 1994 Dec; 35(4):199-219. PubMed ID: 7861943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.
    Cohen JD; Van Putten T; Marder S; Berger PA; Stahl SM
    J Clin Psychopharmacol; 1987 Oct; 7(5):324-9. PubMed ID: 2890671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
    Wiesel FA
    Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
    Meltzer HY; Sommers AA; Luchins DJ
    J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Discontinuation of neuroleptics in chronic schizophrenics. I. Summary of the literature].
    Woggon B
    Int Pharmacopsychiatry; 1979; 14(1):34-56. PubMed ID: 39040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Principles of chemotherapy of paranoid schizophrenia].
    Vanelle JM; Loloum T
    Encephale; 1991; 17(4):235-40. PubMed ID: 1683623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The psychoprophylactic importance of treatment with depot neuroleptics in schizophrenia].
    Chiriţă V; Stanciu J; Pirozynski T
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):497-500. PubMed ID: 2576888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroleptics and the natural course of schizophrenia.
    Wyatt RJ
    Schizophr Bull; 1991; 17(2):325-51. PubMed ID: 1679255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of neuroleptics in a attempt at understanding the vulnerability to schizophrenia].
    Meurice E
    Acta Psychiatr Belg; 1992; 92(6):339-54. PubMed ID: 1364282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of sodium nucleinate in the therapy of schizophrenia].
    Shestakov SV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1979; 79(5):623-7. PubMed ID: 36727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic, pharmacologic, and psychosocial factors influencing response to neuroleptics.
    Kane JM
    Psychopharmacol Bull; 1992; 28(3):227-9. PubMed ID: 1362275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is rehospitalization a measure of the efficacy of neuroleptics in the treatment of schizophrenia?
    Bourin M; Jolliet P; Hery P; Guitton B
    Int J Psychiatry Clin Pract; 1998; 2(4):275-8. PubMed ID: 24927091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties.
    Möller HJ
    Eur Neuropsychopharmacol; 1993 Mar; 3(1):1-11. PubMed ID: 8097126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics.
    Corson PW; Nopoulos P; Miller DD; Arndt S; Andreasen NC
    Am J Psychiatry; 1999 Aug; 156(8):1200-4. PubMed ID: 10450260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to neuroleptic drugs as a device for classifying schizophrenia.
    Brown WA; Herz LR
    Schizophr Bull; 1989; 15(1):123-9. PubMed ID: 2566199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How high is the relapse rate in schizophrenia?
    Johnstone EC; Geddes J
    Acta Psychiatr Scand Suppl; 1994; 382():6-10. PubMed ID: 7916528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.